Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
life sciences
national blog main
4
×
national top stories
opioid
4
×
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
bristol-myers squibb
cancer
cancer immunotherapy
deals
drug prices
eli lilly
fda
johnson & johnson
nonalcoholic steatohepatitis
sanofi
What
drug
4
×
roundup
approval
bio
advanced
ahead
alkermes
alnylam’s
ambien
american
annual
antipsychotic
asco
attendees
attention
benefits
bff
biogen’s
biopharmaceutical
biotech
camp’s
cancer
cash
caveats
chicago
city
clinical
combinations
commonly
community’s
companies
conference
convo
days
deals
designed
devoted
disease
earlier
easl
Language
unset
Current search:
opioid
×
" national blog main "
×
drug
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More